Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats

Journal of Hepatology

Volumn 27, Issue 1, 1997, Pages 176-184

  Zanninelli, Giuliana ^a   Choudury, Ruksana ^b   Loréal, Oliver ^a   Guyader, Dominique ^a   Lescoat, Gérard ^a   Arnaud, Josiane ^c   Verna, Roberto ^d   Cosson, Bertrand ^a   Singh, Surinder ^b   Hider, Robert C ^b   Brissot, Pierre ^a  

^a INSERM   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d NONE

Author keywords

Bile; Hydroxypyridinones; Iron; Iron overload; Non transferrin bound iron; Oral chelation; Rat

Indexed keywords

2 ETHYL 3 HYDROXY 1 (2 HYDROXYETHYL) 4 PYRIDINONE; 3 HYDROXY 1 (3 HYDROXYPROPYL) 2 METHYL 4 PYRIDINONE; 3 HYDROXY 4 PYRIDONE DERIVATIVE; CP 117; CP 165; DEFERIPRONE; IRON; IRON 55; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE FLOW; BILIARY EXCRETION; CONTROLLED STUDY; DRUG HYDROLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRON CHELATION; IRON OVERLOAD; LIPID PEROXIDATION; LIVER METABOLISM; LIVER WEIGHT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0030740083     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80299-1     Document Type: Article

References (29)

1. Brissot P, Wright TL, Ma WL, Weisiger RA. Efficient clearance of non-tranferrin bound iron by rat liver: implications for hepatic iron loading in iron overload states. J Clin Invest. 76:1985;1463.
2. Wright TL, Lake JR. Mechanisms of transport of non-transferrin-bound iron uptake by rat liver. Role of membrane potential difference. J Biol Chem. 263:1988;1842.
3. Grohlic D, Morley GD, Bezkorovainy A. Some aspects of iron uptake by hepatocytes in suspension. Int J Biochem. 10:1979;803.
4. Wright TL, Brissot P, Ma WL, Weisiger R. Characterization of non-transferrin-bound iron clearance by rat liver. J Biol Chem. 261:1986;10909.
5. Brissot P, Zanninelli G, Guyader G, Zeind J, Golland JL. Biliary excretion of non-transferrin bound iron in rats: pathogenetic importance in iron-overload disorders. Am J Physiol. 267:1994;G135.
6. Hershko C, Graham G, Bates GW, Rachmilevits EA. Nonspecific serum iron in thalassaemia: an abnormal serum iron of potential toxicity. Br J Haematol. 40:1978;255.
7. Peters SW, Jones BM, Jacobs A, Wagstaff M. "Free iron" and lipid peroxidation in the plasma of patients with iron overload. Spik G, Montreuil R, Crichton RR, Mazurier J. Proteins of Iron Storage and Transport. 1985;321 Elsevier, New York.
8. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process. Hepatology. 11:1990;127.
9. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Lowmolecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci Lond. 68:1985;463.
10. Jacobs A. Low molecular intracellular iron transport compounds. Blood. 50:1977;434.
11. Brissot P, Deugnier Y. Normal iron metabolism. McIntyre N, Benhamou JP, Bircher J, Rizzeto M, Rodes J. Oxford Texbook of Clinical Hepatology. 1991;221 Oxford University Press, Oxford.
12. Porter JB, Hoyes HP, Abeysinghe R, Huehns ER, Hider RC. Animal toxicity of iron chelator L1. Lancet. ii:1989;459.
13. Olivieri NF. Long-term therapy with deferiprone. Acta Haematol. 95:1996;37.
14. Hider RC, Epemolu RO, Singh S, Porter JB. Iron chelator design. Adv Expt Med Biol. 356:1994;343.
15. Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, et al. Syntheis, physicochemical properties and biological evaluation on N-substituted 2-alkyl-3-hydroxy-4(1h)-pyridinones: orally active iron chelators with clinical potential. J Med Chem. 20:1993;2448.
16. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel R. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest. 71:1983;429.
17. Craven CM, Alexander J, Eldridge M, Kushner JP, Berstein S, Kaplan J. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: a rodent model for hemochromatosis. Proc Natl Acad Sci USA. 84:1987;3457.
18. Barry M, Sherlock S. Measurements of liver iron concentration in needle-biopsy specimens. Lancet. i:1971;100.
19. Hider RC, Hall AD. Clinically useful chelators tripositive elements. Prog Med Chem. 28:1991;41.
20. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunnh F. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 304:1981;319.
21. Brissot P, Deugnier Y. Genetic Hemochromatosis. McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J. Oxford Textbook of Clinical Hepatology. 948:1991;University Press, Oxford.
22. Porter JB, Hider RC, Huehns ER. Update on the hydroxypyridinone oral iron-chelating agents. Sem Hematol. 27:1990;95.
23. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. II. Clinical observations. Br J Haematol. 76:1990;301.
24. Olivieri N, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeteon DM, Koren G. Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Eng J Med. 332:1995;918.
25. Porter JB, Huehns ER, Hider RC. The development of iron chelating drugs. Hershko C. Bailliére's Clinical Haematology. 2:1989;257 Baillière-Tindall, London.
26. Brittenham GM. Development of iron chelating agents for clinical use. Blood. 80:1992;569.
27. Lesage GD, Kost LJ, Barham SS, LaRusso NF. Biliary excretion of iron from hepatocyte lysosomes in the rat. A major excretory pathway in experimental iron overload. J Clin Invest. 77:1986;90.
28. Lévy P, Dumont M, Brissot P, Letreut A, Favier A, Deugnier Y, et al. Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats. Gastroenterology. 101:1991;1673.
29. Hider RC, Choudhury R, Rai BL, Dehkordi L, Singh S. Design of orally active iron chelators. Acta Haematol. 95:1996;6.